News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Apar Ganti, MD, University of Nebraska Medical Center

Articles by Apar Ganti, MD, University of Nebraska Medical Center

Q & A and Final Thoughts

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Recent Progress in the Treatment of SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Introduction and Identifying Predictive Biomarkers

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Latest Updated Articles

Role of Newer Agents in the Treatment & Patient Selection
Published: August 20th 2020 | Updated:
Advice on Toxicity Management for SCLC Therapy
Published: August 20th 2020 | Updated:
$Data on FDA Approved Therapy for Relapsed/Refractory SCLC$
Data on FDA Approved Therapy for Relapsed/Refractory SCLC
Published: August 20th 2020 | Updated:
Q & A and Final Thoughts
Published: August 20th 2020 | Updated:
Recent Progress in the Treatment of SCLC
Published: August 20th 2020 | Updated:
$Use of I/O Regimen in Relapsed/Refractory SCLC$
Use of I/O Regimen in Relapsed/Refractory SCLC
Published: August 20th 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies